Most BCI news is still about experimental brain implants. But there's another side of this field — quieter, yet already inside more than a million people — that treats real diseases, gets reimbursed by insurance, and brings in billions of dollars a year. That's "neuromodulation": devices that send gentle electrical currents to retune neural circuits firing out of sync. And in 2025 it crossed a major line: the first device that "listens" to the brain and adjusts its own treatment was approved, a world first.
Humana Covers BlueWind Tibial Neuromodulation Across 11 Million Medicare Advantage Members
BlueWind Medical announced in early October 2026 that Humana has begun covering implantable tibial neuromodulation therapy for urgency urinary incontinence, including BlueWind's Revi System, across its Medicare Advantage membership of about 11 million enrollees. The coverage decision is backed by multi-year OASIS clinical data and a new AMA Category I CPT code for subfascial tibial neuromodulation. The move comes as Humana's 2027 Star Ratings improved sharply, with 95% of members in 4 star or higher plans, a shift the company's margin-recovery story leans on heavily. Humana's narrative projects $185.9 billion in revenue and $3.4 billion in earnings by 2029, requiring 8.5% yearly revenue growth and a $2.1 billion earnings increase from $1.3 billion today, with a fair value estimate of $430.70. The BlueWind coverage news itself is helpful but not a primary catalyst, while tighter oversight of diagnosis coding remains the biggest near-term risk.
BlueWind Medical · Demand · Positive Humana's coverage decision makes BlueWind's Revi System reimbursable for ~11 million Medicare Advantage enrollees, driving adoption of its product.
HUM · Regulation · Positive Humana began covering implantable tibial neuromodulation (BlueWind's Revi System) across its ~11 million Medicare Advantage members, expanding covered benefits.
Medtronic Q1 Revenue Rises 13.7% to $9.756 Billion as CAS Tops $2 Billion
Medtronic plc reported 13.7% organic and reported topline growth in its first quarter, with revenue reaching $9.756 billion and adjusted earnings of $1.45 per share. Double-digit year-over-year growth was seen across all major segments, with Cardiovascular up 19.5%, Diabetes up 16.9%, Neuroscience up 10.3% and Medical Surgical up 10%, though an extra fiscal week added approximately $570 million to quarterly revenue. CFO Thierry Piéton said the Cardiac Ablation Solutions segment is annualizing at more than $2 billion in revenue, and the unit surpassed $2 billion in trailing 12-month revenue in Q1 FY27, ahead of management's target. The company made a $700 million strategic investment in Cornerstone Robotics that includes rights to distribute the Sentire Surgical System in select markets outside the US, complementing its existing Hugo robotic-assisted surgery system. Medtronic carries a market capitalization of almost $109.3 billion, with $37.54 billion in revenue over the prior twelve months, an operating margin of 19.33% and a net margin of 13.93%; the stock trades at a trailing price-to-earnings multiple of 22x and a forward P/E of 14.93x. Hedge fund holdings rose to 67 in the second quarter of 2026 from 60 in the prior quarter, while BlackRock is the largest institutional investor with 114.02 million shares, or 8.91% of outstanding shares.
Cornerstone Robotics · Capital · Positive Medtronic made a $700 million strategic investment in Cornerstone Robotics including distribution rights to its Sentire Surgical System.
Inspire Medical Systems Wins Category I CPT Codes for Inspire V
Inspire Medical Systems announced in October 2026 that the AMA CPT Editorial Panel approved new Category I CPT codes specifically covering the Inspire V system, with the codes set to take effect on January 1, 2028 and to guide future Medicare payment determinations. The coding milestone signals growing clinical acceptance of Inspire's closed-loop implantable therapy for obstructive sleep apnea and sets the stage for more standardized reimbursement across payers. The approval ties directly into the proposed 2027 Medicare facility reimbursement rates for Inspire V, which point to higher payments for hospitals and ASCs alongside a modest cut to physician fees. Inspire Medical Systems' narrative projects $991.6 million in revenue and $74.2 million in earnings by 2029, requiring 3.3% yearly revenue growth and a $60.8 million earnings decrease from $135.0 million today, while some analysts assume revenue grows only about 1.8% annually and earnings fall toward roughly US$29.0 million. The company's biggest immediate risk remains that ongoing coding education and WISeR disruption keep weighing on revenue and margins longer than expected.
INSP · Regulation · Positive AMA CPT Editorial Panel approved new Category I CPT codes for the Inspire V system, standardizing reimbursement and signaling clinical acceptance.
Medtronic Raises Fiscal 2027 Guidance as Revenue Jumps 13.7%
Medtronic reported first-quarter fiscal 2027 revenue of $9.76 billion, up 13.7% from a year earlier, and raised its full-year outlook, with adjusted diluted EPS climbing 15.1% to $1.45 and GAAP EPS rising 40.7% to $1.14. Management now expects organic revenue growth of 7.25%-7.75% for fiscal 2027, up from 6.75%-7.25% previously, and lifted adjusted EPS guidance to $5.94-$6.00. The quarter included an extra selling week that added about $570 million to revenue, so the headline growth rate should not be expected to repeat. Cardiovascular delivered strong growth, while Neuroscience, Medical Surgical and Diabetes also posted high-single-digit or double-digit organic growth. At a share price of around $89-$90, the stock trades at roughly 15 times the midpoint of the adjusted EPS forecast, versus about 22 times trailing earnings, while paying a quarterly dividend of $0.72 per share, or $2.88 a year, for a yield of roughly 3.2%-3.3%. Medtronic is also expanding its Affera cardiac mapping and ablation system, investing in Pi-Cardia and Cornerstone Robotics, and has acquired Scientia Vascular and SPR Therapeutics, with a planned separation of its Diabetes business.
Medtronic Wins Category I CPT Codes for Altaviva and Symplicity Spyral
Medtronic announced that the American Medical Association has approved new Category I Current Procedural Terminology codes for two of its technologies, the Altaviva implantable tibial neuromodulation device for urge urinary incontinence and the Symplicity Spyral renal denervation system for uncontrolled hypertension. The new codes, which replace existing Category III codes, take effect in January 2028. Category I codes are permanent codes assigned to procedures the AMA deems well established, widely performed across the United States, and supported by robust clinical evidence, and while they can help support physician payment and inform commercial payer coverage decisions, they do not determine coverage, reimbursement, clinical superiority, or patient access. The Altaviva device was approved by the U.S. Food and Drug Administration in September 2025 for urge urinary incontinence, a condition affecting 16 million adults in the United States, and is placed under the skin near the ankle in a minimally invasive procedure. The Symplicity Spyral system was finalized for Medicare coverage in October 2025, and Medtronic said its SPYRAL HTN global clinical program is the most comprehensive studying renal denervation, with more than 5,000 patients and experience in over 40,000 patients globally.
MDT · Regulation · Positive AMA approved permanent Category I CPT codes for Medtronic's Altaviva and Symplicity Spyral devices, supporting physician payment and payer coverage.
Neuromod Appoints Joe Ghiz as Chief Commercial Officer, Shannon Basham as VP of Channel Development
Neuromod Devices has announced the appointment of Joe Ghiz as Chief Commercial Officer and Shannon Basham as VP of Channel Development. Ghiz joins Neuromod's senior management team and will lead the company's global commercial function as it continues to strengthen its position as the category creator in tinnitus care, with CEO Dr. Ross O'Neill citing robust clinical evidence, global regulatory approval, and broad commercial adoption as positioning the company for rapid scaling to address the needs of 740 million tinnitus sufferers worldwide. Ghiz joins from Align Technology, the company behind Invisalign, where he helped create and scale the clear aligner category and built a $10 billion company, and previously spent over a decade at Johnson & Johnson Vision Care in leadership roles spanning sales, marketing, and business development. Basham brings more than 20 years of experience in the hearing care industry, having most recently served as Senior Director of Audiology for Sonova Group in the United States of America, where she was the market-facing head of audiology for the Phonak and Unitron wholesale businesses. The appointments support Neuromod's goal of positioning its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire, as a new standard of care in ENT and audiology practices.
Onward Medical H1 2026 Revenue Surges 250% as ARC-EX Sales Top 159 Systems
Onward Medical reported H1 2026 revenue of EUR4.2 million, up 250% year-over-year, with EUR3.4 million coming from product revenues and gross profit of EUR2.9 million at roughly 70% gross margin. The company sold or supplied 159 ARC-EX systems via paid evaluation in H1 2026, more than a 5x increase year-over-year, including 89 units sold in Q2 2026 alone, with the device now available in over 150 clinics worldwide, including over 130 in the US, covering an estimated 35-40% of US facilities managing spinal cord injury. Operating expenses rose to EUR26.3 million from EUR21 million in H1 2025, producing an operating loss of EUR23.3 million and a net loss of EUR24.7 million, while cash burn reached EUR26 million. The company ended June 2026 with EUR81.5 million in cash, up from EUR68.1 million at the start of the year, after raising over EUR40 million in new equity capital including EUR25 million from EQT Life Sciences, and secured a debt facility of up to EUR50 million from BlackRock replacing its existing loan, with EUR20 million drawn at closing, extending its cash runway into Q1 2028. On the clinical side, the EMPOWER-BP pivotal trial has enrolled 22 participants across 14 active sites, with interim analysis expected by end of Q1 or early Q2 2027, and the company completed its CMS coding submission with a decision expected in Q4 2026.
Onward Medical N.V. · Demand · Positive ARC-EX systems sold/supplied 159 units in H1 2026, more than 5x YoY, with 89 in Q2 alone and availability in over 150 clinics.
Onward Medical N.V. · Capital · Positive Revenue surged 250% to EUR4.2M with ~70% gross margin, and the company raised over EUR40M equity plus a EUR50M BlackRock debt facility, extending runway into Q1 2028.
EQT Life Sciences · Capital · Positive EQT Life Sciences invested EUR25M of the over EUR40M new equity capital raised by Onward Medical.
NeuroPace Beats Q2 Estimates, Raises 2026 Revenue Guidance to $99.5-$101.5 Million
NeuroPace reported a second-quarter 2026 loss per share of 18 cents, beating the Zacks Consensus Estimate by 5.3% and improving from a loss of 30 cents a year earlier. Revenue rose 17.1% year over year to $22.8 million, led by the RNS System, whose revenues totaled $22.5 million, up 21.3%, while service revenues fell to $302,000 from $937,000 a year ago following the DIXI Medical wind-down. Adjusted gross margin contracted 60 basis points to 83.4%, and the adjusted operating loss narrowed to $2.8 million from $5 million. Management raised full-year 2026 revenue guidance to $99.5-$101.5 million from $99-$101 million, reflecting expected service revenues of about $1 million, up from roughly $500,000 previously, while the RNS revenue growth outlook remains 21%-23%. The company also lifted its adjusted gross margin outlook to 82%-83% and narrowed its expected adjusted EBITDA loss to $7.5 million-$8.5 million, though consensus estimates have trended downward over the past month.
Brain-computer interfaces accelerate toward market as listed companies race to secure a share of a hundred-billion-yuan track
Brain-computer interface technology is accelerating its move from the laboratory into clinical and consumer markets. The global market is expected to exceed 360 billion yuan by 2035, with China likely to account for more than 30 percent of that share. Neuralink has announced completion of the world's first brain-computer interface surgery implanted through the dura mater, while China's first subdural implantable brain-computer interface system has also begun national Class III medical device registration clinical trials. Companies listed in both A-share and Hong Kong markets, such as Wision Medical, Sanbo Brain Hospital, and MicroPort NeuroTech, have already achieved commercial revenue through non-invasive rehabilitation, clinical data assets, and implantable products. On the policy front, brain-computer interfaces have been included in the future industries section of the 15th Five-Year Plan. Beijing, Shanghai, and Guangdong have introduced targeted support policies, and an industry standardization technical committee has also been established. Institutions expect 2027 to become the first year of commercial explosion for brain-computer interfaces.
2172.HK · Demand · Positive MicroPort NeuroTech has achieved commercial revenue through implantable products, benefiting from the accelerating BCI market.
301293.CS · Demand · Positive Sanbo Brain Hospital leverages clinical data assets, positioned to benefit from the BCI market growth.
688580.CG · Demand · Positive Wision Medical has commercial revenue from non-invasive rehabilitation, poised to grow with the BCI market expansion.
United States
